Takeda Pharmaceutical Co ( (JP:4502) ) just unveiled an announcement.
Takeda Pharmaceutical Co. has announced an update on its acquisition of own shares, acquiring 7,029,800 shares at a cost of JPY 29,833,229,600 between February 17 and February 28, 2025. This acquisition is part of a larger plan approved by the Board of Directors to repurchase up to 28.5 million shares, with a total acquisition cost of up to JPY 100 billion, scheduled to be completed by May 31, 2025. This strategic move is expected to impact the company’s market positioning and shareholder value.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. The company focuses on creating better health outcomes through life-transforming treatments in areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With operations in approximately 80 countries, Takeda is committed to improving patient experiences and advancing treatment options through its diverse pipeline.
YTD Price Performance: 1.02%
Average Trading Volume: 16,380
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $45.67B
Learn more about 4502 stock on TipRanks’ Stock Analysis page.